In the Spotlight: A Personal Side of Our CEO
25 July 2025
Swiss Rockets Featured in Finanz und Wirtschaft: Strong Industry Recognition and Promising Clinical Outlook
16 June 2025
Torpedo Pharmaceuticals AG’s Mission is to set a New Standard in Cancer Therapy with Innovative Radiopharmaceuticals
10 April 2025
Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)
10 September 2024
[Terbium-161] Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [Lutetium-177]Lu-PSMA-617
24 February 2024
Cleveland Clinic Appoints Prof. Alex A. Adjei, M.D., Ph.D., as Chair of Taussig Cancer Institute
30 June 2022
Alex A. Adjei is the recipient of the 2021 ESMO Lifetime Achievement Award
12 August 2021
Radiation doses from Terbium-161 and Lutetium-177 in single tumour cells and micrometastases
19 May 2020
Production and characterization of no-carrier-added Terbium-161 as an alternative to the clinically-applied Lutetium-177 for radionuclide therapy
10 July 2019
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
27 May 2019
your name
your email
organization name
